Intracoronary physiology-guided percutaneous coronary intervention in patients with diabetes.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 21 03 2023
accepted: 02 06 2023
medline: 25 8 2023
pubmed: 20 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

The risk of vessel-oriented cardiac adverse events (VOCE) in patients with diabetes mellitus (DM) undergoing intracoronary physiology-guided coronary revascularization is poorly defined. The purpose of this work is to evaluate the risk of VOCE in patients with and without DM in whom percutaneous coronary intervention (PCI) was performed or deferred based on pressure-wire functional assessment. This is a retrospective analysis of a multicenter registry of patients evaluated with fractional flow reserve (FFR) and/or non-hyperaemic pressure ratio (NHPR). Primary endpoint was a composite of VOCE including cardiac death, vessel-related myocardial infarction (MI), and ischemia-driven target vessel revascularization (TVR). A large cohort of 2828 patients with 3353 coronary lesions was analysed to assess the risk of VOCE at long-term follow-up (23 [14-36] months). Non-insulin-dependent-DM (NIDDM) was not associated with the primary endpoint in the overall cohort (adjusted Hazard Ratio [aHR] 1.18, 95% CI 0.87-1.59, P = 0.276) or in patients with coronary lesions treated with PCI (aHR = 1.30, 95% CI 0.78-2.16, P = 0.314). Conversely, insulin-dependent diabetes mellitus (IDDM) demonstrated an increased risk of VOCE in the overall cohort (aHR 1.76, 95% CI 1.07-2.91, P = 0.027), but not in coronary lesions undergoing PCI (aHR 1.26, 95% CI 0.50-3.16, P = 0.621). Importantly, in coronary lesions deferred after functional assessment IDDM (aHR 2.77, 95% CI 1.11-6.93, P = 0.029) but not NIDDM (aHR = 0.94, 95% CI 0.61-1.44, P = 0.776) was significantly associated with the risk of VOCE. IDDM caused a significant effect modification of FFR-based risk stratification (P for interaction < 0.001). Overall, DM was not associated with an increased risk of VOCE in patients undergoing physiology-guided coronary revascularization. However, IDDM represents a phenotype at high risk of VOCE.

Identifiants

pubmed: 37338598
doi: 10.1007/s00392-023-02243-y
pii: 10.1007/s00392-023-02243-y
pmc: PMC10449663
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1331-1342

Informations de copyright

© 2023. The Author(s).

Références

J Diabetes Complications. 2013 Jan-Feb;27(1):70-4
pubmed: 23079124
EuroIntervention. 2019 Feb 20;14(14):1435-1534
pubmed: 30667361
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Cardiovasc Diabetol. 2015 Oct 07;14:135
pubmed: 26446829
J Am Coll Cardiol. 2003 Apr 16;41(8):1387-93
pubmed: 12706936
Diabetes. 2003 Jul;52(7):1851-6
pubmed: 12829656
JACC Cardiovasc Interv. 2014 May;7(5):471-81
pubmed: 24852802
Int J Cardiol. 2017 Oct 15;245:63-68
pubmed: 28789845
J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129
pubmed: 34895950
J Am Coll Cardiol. 2014 Sep 23;64(12):1189-97
pubmed: 25236509
JACC Cardiovasc Interv. 2018 Dec 24;11(24):2467-2476
pubmed: 30573057
JAMA Cardiol. 2020 Mar 1;5(3):272-281
pubmed: 31913433
JAMA Cardiol. 2019 Sep 1;4(9):857-864
pubmed: 31314045
Circulation. 2021 Oct 26;144(17):1380-1395
pubmed: 34521217
Am J Cardiol. 2018 Jun 15;121(12):1505-1511
pubmed: 29751955
Circ Cardiovasc Interv. 2015 Jun;8(6):e002328
pubmed: 26025219
Circ Cardiovasc Interv. 2022 May;15(5):e011728
pubmed: 35485232
J Am Coll Cardiol. 1997 Nov 15;30(6):1472-7
pubmed: 9362404
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
J Am Heart Assoc. 2019 Aug 20;8(16):e012741
pubmed: 31387441
J Am Coll Cardiol. 2016 Nov 29;68(21):2247-2255
pubmed: 27884241
Eur Heart J. 2019 Jan 14;40(3):237-269
pubmed: 30165617
J Am Heart Assoc. 2018 Jul 13;7(14):
pubmed: 30006490
Circulation. 2009 Dec 22;120(25):2529-40
pubmed: 19920001
JACC Cardiovasc Interv. 2015 May;8(6):800-811
pubmed: 25999102
Eur Heart J. 2015 Feb 21;36(8):509-15
pubmed: 25336221
JACC Cardiovasc Imaging. 2017 Apr;10(4):451-458
pubmed: 27372016
Catheter Cardiovasc Interv. 2017 Dec 1;90(7):1077-1083
pubmed: 28303683
Eur Heart J. 2021 Dec 1;42(45):4671-4679
pubmed: 34345911
EuroIntervention. 2016 Feb;11(10):1111-7
pubmed: 26874336
Catheter Cardiovasc Interv. 2022 Feb;99(3):736-745
pubmed: 34761492

Auteurs

Roberto Scarsini (R)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy. roberto.scarsini@aovr.veneto.it.
Division of Cardiology, University of Verona, Piazzale A. Stefani 1, 37126, Verona, Italy. roberto.scarsini@aovr.veneto.it.

Matteo Tebaldi (M)

Azienda Ospedali Riuniti Marche Nord, Emodinamica e Cardiologia Interventistica, Pesaro, Italy.

Francesca Rubino (F)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy.
Division of Cardiology, University of Verona, Piazzale A. Stefani 1, 37126, Verona, Italy.

Sara Sgreva (S)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy.
Division of Cardiology, University of Verona, Piazzale A. Stefani 1, 37126, Verona, Italy.

Giovanni Vescovo (G)

Ospedale dell'Angelo, Mestre, Italy.

Marco Barbierato (M)

Ospedale dell'Angelo, Mestre, Italy.

Andrea Vicerè (A)

Istituto di Cardiologia Università Cattolica del Sacro Cuore, Rome, Italy.

Domenico Galante (D)

Dipartimento di Scienze Cardiovascolari Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Concetta Mammone (C)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy.

Mattia Lunardi (M)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy.

Domenico Tavella (D)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy.

Gabriele Pesarini (G)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy.

Gianluca Campo (G)

Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Cona (Ferrara), Italy.

Antonio Maria Leone (AM)

Dipartimento di Scienze Cardiovascolari Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Diagnostic and Interventional Unit Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola, Rome, Italy.

Flavio Luciano Ribichini (FL)

Division of Cardiology, Department of Medicine, Verona University Hospital, Piazzale A. Stefani 1, 37126, Verona, Italy. flavio.ribichini@univr.it.
Division of Cardiology, University of Verona, Piazzale A. Stefani 1, 37126, Verona, Italy. flavio.ribichini@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH